The purpose of this study is to assess the ability of common genetic variants in aggregate to
predict drug-induced QT prolongation in healthy subjects using moxifloxacin.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination